Search the Newsreel

Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 12,980 Shares

Takeda Pharmaceutical insider Nicola Deidre Petal Greenway sold 12,980 shares of the company's stock for a total of $235,067.80. This transaction reduced her holdings by 24.48%, leaving her with 40,049 shares. The sale occurred on August 18th at an average price of $18.11, following …

Alphabet Stock Surged When Its AI Spending Found Customers

Alphabet's stock significantly outperformed the market and its peers over the past year, returning 69.6% compared to the S&P 500's 20.3%. This surge is attributed to its AI spending finding customers, particularly in Google Cloud, which saw 82% revenue growth and improved operating margins. …

Die Parker-Hannifin-Aktie setzt ihre Rally mit zweistelligem Gewinnwachstum fort

SOPHiA GENETICS (NASDAQ: SOPH) officer plans additional 8,000-share sale

An officer at SOPHiA GENETICS (NASDAQ: SOPH), Zhenyu Xu, intends to sell an additional 8,000 shares of common stock under Rule 144, valued at $60,960. These shares are founder shares acquired in 2012 and are held at Morgan Stanley Smith Barney LLC Executive Financial …

Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale

Zenas BioPharma (ZBIO) announced via a Rule 144 notice that its affiliate, Zebra Aggregator, plans to sell up to 1,000,000 common shares through J.P. Morgan Securities LLC on August 19, 2026. This proposed sale has an aggregate market value of $31,910,000 and the shares …

Family trust tied to BridgeBio (NASDAQ: BBIO) plans new stock sale

A family trust associated with BridgeBio Pharma, Inc. (BBIO), the Kumar Haldea Family Irrevocable Trust, intends to sell 30,000 shares of common stock valued at approximately $2.49 million. This sale, detailed in a Form 144 SEC filing, follows previous 10b5-1 sales by Neil Kumar …

Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial?

Ionis Pharmaceuticals, in collaboration with Roche and Chugai, is advancing RG-6299, an antisense therapy for IgA nephropathy, into a global Phase III trial. This move targets an unmet medical need and aligns with Ionis' strategy of leveraging its RNA platform through partnerships for late-stage …

Phibro Animal Health to report Q4 FY26 results on August 26

Phibro Animal Health Corporation (NASDAQ: PAHC) is scheduled to announce its fourth quarter and fiscal year 2026 financial results after market close on Wednesday, August 26, 2026. Management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 am ET …

Guardian Pharmacy CEO to join a Sept. 15 fireside chat for investors

Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced that its President and CEO, Fred Burke, will participate in a fireside chat at the Jefferies Healthcare Services Conference on September 15, 2026. The event, starting at 2:25 p.m. CST, will be accessible via a live audio …

Philip Morris International Inc. stock underperforms Wednesday when compared to competitors despite daily gains

Philip Morris International Inc. (PM) shares increased by 1.23% on Wednesday, closing at $189.93. Despite this gain, the stock underperformed compared to the broader market, as the S&P 500 Index rose by 0.21% and the Dow Jones Industrial Average gained 0.22%. This marks the …

Parker-Hannifin (NYSE: PH) exec sells shares, gifts 95 more

Parker-Hannifin Corp executive Scott Patrick, VP & Pres-Fluid Conn. Grp., reported selling 1,235 shares of the company's common stock on August 17, 2026, at a weighted average price of $1,056.98 per share. Additionally, he gifted 95 shares of common stock on August 18, 2026. …

Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 4.48% on Aug 19: Drivers Behind the Movement

Alpha Teknova at Micro-Cap Virtual Conference: clinical growth in focus

Alpha Teknova recently presented at the Micro-Cap Virtual Conference, highlighting significant growth in its clinical products division and improved financial performance. The company reported record Q2 2025 revenue of $12.2 million and raised its full-year guidance, with adjusted EBITDA expected to turn positive in …

Innate Pharma (IPHA) sells 17.6M shares to fund ADCs, cash runway to Q3 2026

Innate Pharma (IPHA) has successfully raised approximately €30.0 million in gross proceeds, or €27.6 million net, through a private placement of 17,647,059 new ordinary shares at €1.70 each. The funds are primarily intended to support the clinical development of its Nectin-4 ADC IPH4502 and …

Eupraxia (Nasdaq: EPRX) lines up $300M in securities offerings

Eupraxia Pharmaceuticals Inc. (EPRX) has filed an amended Form F-10 shelf prospectus to register up to $300 million in various securities, including common and preferred shares, debt, warrants, subscription receipts, and units. This filing provides a flexible framework for future capital raises over a …

Crinetics Pharmaceuticals to supplement proxy after shareholder suits ahead of $85-per-share Vertex merger

Crinetics Pharmaceuticals announced it will voluntarily supplement its proxy disclosures following shareholder complaints and demand letters regarding the proposed $85.00-per-share merger with Vertex. Despite denying allegations of false or omitted information in the initial proxy, Crinetics will file supplemental disclosures to avoid delays and …

Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow

Madrigal Pharmaceuticals (MDGL) stock appears undervalued based on sales, trading at a P/S ratio of 9.4x compared to an industry average of 11.1x and a fair estimate of 15.0x. Despite a significant 5.4x gain over five years, a recent pullback has prompted a re-evaluation …

Takeda (NYSE: TAK) officer plans sale of 19,651 shares

An officer of Takeda Pharmaceutical Co Ltd (TAK), Andrew Stewart Plump, plans to sell 19,651 shares of common stock through Fidelity Brokerage Services LLC on or about August 19, 2026. The shares, acquired as RSU's and PSU's on August 20, 2020, are held in …

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026 Morgan Stanley 24th Annual Global Healthcare Conference at …

Crinetics (CRNX) projects $1B+ 2030 revenue for Vertex deal

CSCI Reports Earnings — What Canadian Investors Should Know

Pharvaris BV (NASDAQ: PHVS) Share Price, PHVS Stock News, PHVS Share Price & Updates

Smith & Nephew stock drops as CFO John Rogers plans September exit

* Smith+Nephew (SNN [https://seekingalpha.com/symbol/SNN]) said CFO John Rogers will leave the company on Sept. 30 to take up an external position in the U.S. * Rogers will step down from the board immediately, and the company has begun a search for his successor. * …

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) and its officers. The lawsuit, filed on behalf of investors who purchased shares between March 9, 2026, and June 24, 2026, alleges that the company made materially false …

ARS Pharmaceuticals (NASDAQ: SPRY) holder lines up new 50K-share sale

Richard Lowenthal, a holder of ARS Pharmaceuticals (NASDAQ: SPRY) stock, has filed a Rule 144 notice to sell up to 50,000 common shares. This proposed sale, valued at approximately $322,345, is related to a stock option exercise and follows a previous sale of 50,000 …

Telephone and Data Systems, Inc. Announces Dividend on Its Common Share and Series A Common Share for the Third Quarter of 2026, Payable on September 30, 2026

Telephone and Data Systems, Inc. announced a quarterly dividend of $0.04 per Common Share and Series A Common Share. The dividend is payable on September 30, 2026, to shareholders of record as of September 15, 2026. This announcement confirms the company's consistent dividend policy …

Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, purchased 10,000 shares of common stock on August 18, 2026, at $1.06 per share. This transaction increased his direct holdings to 431,421 shares, which include unvested restricted stock units. The insider trade summary indicates …

Price to earnings forward of Sonoma Pharmaceuticals, Inc. – SWB:O8Z

This article provides the "Price to earnings forward" data for Sonoma Pharmaceuticals, Inc. (SWB:O8Z) as traded on the Stuttgart Stock Exchange. The current market status is "closed with no trades" for this specific data point. The content primarily highlights various navigation and informational links …

ConocoPhillips Alaska's Coyote 3SX Begins Oil Production, Under Budget - News and Statistics

ConocoPhillips Alaska has commenced oil production at its Coyote 3SX development in the Kuparuk River Unit on August 7, ahead of schedule and under its $800 million budget. The project, located on Alaska's North Slope, is projected to achieve a peak gross production of …

Q2 Earnings Highlights: Graphic Packaging Holding (NYSE:GPK) Vs The Rest Of The Industrial Packaging Stocks

Q2 Earnings Highlights: Graphic Packaging Holding (NYSE:GPK) Vs The Rest Of The Industrial Packaging Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Graphic …

BioMarin initiated an outperform at BMO as Voxzogo erosion overstated

BMO Capital Markets initiated coverage of BioMarin Pharmaceutical (BMRN) with an "outperform" rating. The firm believes that investors are overstating the potential sales erosion of BioMarin's key treatment, Voxzogo, indicating a potential 46% upside. BioMarin's current trading valuation is also noted to be significantly …

Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong

Supernus Pharmaceuticals (SUPN) has shown strong returns over the past five years, with its stock almost doubling, and still appears undervalued on several measures. Despite a 16.7% return over the last year, which lags behind peers, the company's P/S multiple of 3.4x is below …

JPMorgan Chase & Co. Cuts Telephone and Data Systems (NYSE:TDS) Price Target to $48.00

JPMorgan Chase & Co. has lowered its price target for Telephone and Data Systems (NYSE:TDS) to $48.00 from $51.00, while maintaining an "overweight" rating. This new target suggests a potential upside of 37.77% from the stock's current price. Despite mixed analyst ratings, TDS holds …

Antalpha Platform Holding Co (ANTA) (Q2 2026) Earnings Call Highlights: Revenue Drops 28% Amid ... By GuruFocus

Antalpha Platform Holding Co (ANTA) reported a significant 28% year-over-year revenue drop in Q2 2026, totaling $12.2 million, primarily due to decreased financing activity and lower average loan balances. The company experienced a GAAP operating loss of $25.1 million, largely influenced by fair value …

Antalpha Platform Holding Co (ANTA) (Q2 2026) Earnings Call Highlights: Revenue Drops 28% Amid ...

This article first appeared on GuruFocus. Total Revenue: $12.2 million, down 28% year-over-year from $17 million in Q2 2025. Revenue Excluding Cango Facility: Declined 15% year-over-year, reflecting lower average loan balances. Technology Financing Fees: $7.7 million, down 40% year-over-year. Technology Platform Fees: $4.5 million, …

Phillips 66’s best week of the year tests a record zone as refining peers confirm the move

PSX jumped 14.6% to close just 1.1% below its 52-week high, with the Oil & Gas Refining & Marketing group showing broader confirmation than the Energy sector overall.